Anupam Dalal - Sep 26, 2022 Form 4 Insider Report for Aadi Bioscience, Inc. (AADI)

Role
Director
Signature
/s/ Stephen Rodin, as Attorney-in-Fact
Stock symbol
AADI
Transactions as of
Sep 26, 2022
Transactions value $
$4,000,000
Form type
4
Date filed
9/27/2022, 07:20 PM
Previous filing
Jun 17, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AADI Common Stock Award $4M +320K +20.92% $12.50 1.85M Sep 26, 2022 See footnote F1
holding AADI Common Stock 1.13K Sep 26, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 1,572,698 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 276,704 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.